Curcumin Enhances Gefitinib Therapy in Lung Cancer
Author Information
Author(s): Lee Jen-Yi, Lee Yee-Ming, Chang Gee-Chen, Yu Sung-Liang, Hsieh Wan-Yu, Chen Jeremy J. W., Chen Huei-Wen, Yang Pan-Chyr
Primary Institution: National Yang-Ming University, Taipei, Taiwan
Hypothesis
Can curcumin improve the effectiveness of gefitinib in non-small cell lung cancer (NSCLC) patients resistant to gefitinib?
Conclusion
Curcumin enhances the anti-tumor effects of gefitinib in NSCLC and reduces gastrointestinal side effects.
Supporting Evidence
- Curcumin was found to inhibit cell proliferation in gefitinib-resistant NSCLC cell lines.
- Combination treatment with curcumin and gefitinib showed significant tumor growth inhibition in xenograft models.
- Curcumin reduced gefitinib-induced gastrointestinal damage and improved survival rates in mice.
Takeaway
Curcumin is a natural substance that can help make a cancer medicine called gefitinib work better and cause fewer stomach problems.
Methodology
The study involved screening 598 herbal compounds, testing curcumin's effects on NSCLC cell lines and xenograft models, and analyzing tumor growth and protein expression.
Potential Biases
Potential bias in selecting compounds and interpreting results from animal models.
Limitations
The study primarily focused on in vitro and in vivo models, which may not fully represent human responses.
Participant Demographics
The study involved various NSCLC cell lines, including those from Asian and Caucasian backgrounds.
Statistical Information
P-Value
0.0006
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website